NEWS RELEASE

2021.05.12

Amplia Therapeutics has publshed a pres releaes regarding the AMP945 and AMP886 efficacy evaluation study for NASH we have provied.

Amplia Therapeutics, which is our client, has announced the results of pharmacology study using a STAM™ mouse model.

 

For detail information, see the Amplia's press release.

https://www.ampliatx.com/site/PDF/fd3f2d1f-9d2b-4fff-a6ad-13a3ea8d4956/ATXFAKInhibitorsReduceFibrosisinAnimalModelofNASH